Fundada para Resolver um Problema Real.
O campo dos EVs tem potencial extraordinário. O que faltava era infraestrutura. Estamos construindo isso.
Por Que a BioThera Solutions Construiu uma Plataforma de Biofabricação de EV?
BioThera Solutions was founded to address a critical gap in the extracellular vesicle (EV/exosome) field: the absence of scalable, standardized, and reproducible manufacturing required to bring EV technologies of all kinds into real-world application. We set out to build that infrastructure as a platform, not a single product, and to lay the foundation for every application that comes after the first.
Apesar das crescentes evidências científicas para os EVs como sistemas de entrega biológica potentes, a indústria tem lutado para traduzir descobertas de laboratório em produtos comercialmente viáveis e consistentemente fabricados. O problema não é a biologia, é a infraestrutura.
We are building that infrastructure, and we started where the need was most immediate. Interest in exosome-based skincare has grown quickly, driven by genuine scientific interest and consumer demand, yet the market is crowded with products making bold claims, backed by inadequate characterization, inconsistent particle concentrations, and little regulatory transparency. There is real demand, and a real absence of material that meets rigorous scientific standards.
BioThera was built to close that gap. We bring biomanufacturing expertise to a space that has been underserved by rigorous science: characterization in line with MISEV2023, measured particle concentrations, and documentation for every batch. Our research and development has produced proprietary, patent-pending technology and the capacity to manufacture at scale. For cosmetic applications, we license our technology exclusively to Vesera™, a skincare company, and produce the material it uses.
Cosmetic applications are where the platform first meets the market, and they are only the beginning. The infrastructure we are building, from manufacturing and characterization to the evidence base, is designed to carry across biological sources and applications. Our current platform uses plant-derived vesicles; as we grow, our research extends to animal-derived sources, including human stem cell-derived vesicles, and to therapeutic applications, an important focus for our team.
Build the integrated extracellular vesicle platform the field has been missing: standardized, characterized vesicles, engineered to work across biological sources, for applications that begin with cosmetics and extend well beyond them.
With cosmetic applications as our first commercial use, we are establishing the manufacturing infrastructure, characterization rigour, and evidence base that credible EV applications, including therapeutic ones, require.
To define what credible, science-led EV technology looks like, and to build the biomanufacturing backbone the extracellular vesicle field needs to mature, across every application it reaches.
We are in the early chapters of the EV era. Our ambition is to set the standard for the field by building the manufacturing foundation, characterization rigour, and evidence base that scientists, clinicians, partners, and regulators can trust.
O Que Defendemos
Transparência Científica Radical
Não fazemos afirmações que não possamos substanciar. Cada especificação de produto, resultado de caracterização e status regulatório é comunicado com precisão. Linguagem vaga e hipérbole de marketing não têm lugar em como operamos.
Excelência Sem Compromisso
Padrões de fabricação, protocolos de caracterização, qualidade de formulação, aplicamos o mesmo rigor em cada etapa, independentemente de onde estamos no ciclo de desenvolvimento. A qualidade é incorporada, não inspecionada.
Inovação
O espaço dos EVs é inicial. A infraestrutura de fabricação necessária para tornar os EVs clinicamente e comercialmente viáveis ainda não existe completamente, estamos construindo. Isso requer criatividade científica genuína e coragem técnica.
Execução
Ideias em biotecnologia são abundantes. Execução rigorosa e confiável é rara. Fechamos a lacuna entre o potencial científico e a implantação no mundo real, consistentemente, dentro do prazo e conforme especificação.
Ottawa, Ontario, Canada
BioThera Solutions tem sede em Ottawa, Ontário. Nossa localização proporciona proximidade com órgãos regulatórios, um ecossistema de ciências da vida em crescimento, e os colaboradores clínicos e de pesquisa centrais ao nosso trabalho.
477-150 Louis-Pasteur Private Ottawa, Ontario K1N 6N5 Canada
Universidade de Ottawa: Complexo STEM · Ottawa, Ontario
Company Clarification
BioThera Solutions (Canada) is an independent biotechnology firm specializing in extracellular vesicle (EV) technology. We have no affiliation with Bio-Thera Solutions, Ltd. (China), which focuses on biosimilars and antibody-drug conjugates (ADCs). Our mission is to build the integrated platform that extracellular vesicle technology requires, from research and intellectual property to manufacturing, across the sources and applications of extracellular vesicles.
BioThera Solutions trabalha exclusivamente com parceiros selecionados.
Trabalhamos de forma seletiva com parceiros de pesquisa, clínicos e industriais quando há forte alinhamento científico e estratégico.
Consultas sobre parceria são analisadas individualmente.
Consultar Sobre ParceriaESG e responsabilidade
BioThera Solutions operates with environmental, social, and governance (ESG) principles built into how we work. Our current vesicles are derived from medicinal plants rather than animal or human tissue, and our biomanufacturing process is designed to be scalable and resource-efficient. We are transparent about our science and communicate clearly with clinical partners, suppliers, and the broader research community. Our governance practices are aligned with Health Canada cosmetic notification requirements, and our scientific reporting follows MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines. Sustainability and ethical conduct are part of how we build for the long term.